Plasma Renin Activity: What This Test Actually Measures

How the PRA Test Works at the Molecular Level

Renin is a protease secreted by juxtaglomerular cells in the kidney. PRA quantifies its enzymatic activity, not the mass of renin protein itself. A collected plasma sample is incubated at 37°C, and the rate at which angiotensin I accumulates during that incubation window becomes the reported value in ng/mL/hr [1].

This functional assay differs from direct renin concentration (DRC), which uses an immunoassay to measure renin mass in mIU/L. The 2016 Endocrine Society Clinical Practice Guideline on primary aldosteronism notes that either PRA or DRC can be used for the aldosterone-to-renin ratio (ARR), but the diagnostic cutoffs differ depending on which renin metric is chosen [2]. PRA captures active enzymatic conversion. DRC captures total renin protein, including prorenin that may not be enzymatically active.

The distinction matters clinically. In patients taking direct renin inhibitors like aliskiren, PRA falls while DRC rises, because the drug blocks renin's catalytic site without reducing renin mass [3]. Choosing the wrong assay in that setting produces misleading results.

Pre-analytical handling is strict. Blood must be drawn into a chilled EDTA tube, kept on ice, and centrifuged within 30 minutes. Room-temperature delays allow ongoing angiotensin I generation ex vivo, artificially inflating the result. A 2018 analysis in the Journal of Clinical Endocrinology & Metabolism found that samples processed at room temperature showed PRA values up to 40% higher than ice-handled counterparts [4].

Normal Plasma Renin Activity Ranges

Reference ranges for PRA vary by assay platform, patient posture, sodium intake, and age. A commonly cited upright ambulatory range is 0.25 to 5.82 ng/mL/hr, while supine values run lower at 0.15 to 2.33 ng/mL/hr [5].

Posture has a large effect. Standing for two hours before blood draw stimulates the sympathetic nervous system and reduces renal perfusion pressure, both of which trigger renin release from juxtaglomerular cells [1]. The Endocrine Society guideline recommends that patients sit upright for at least two hours before sampling and that samples be drawn mid-morning, between 8 AM and 10 AM [2].

Sodium intake shifts the range significantly. A high-sodium diet suppresses renin. A low-sodium diet stimulates it. In NHANES III population data, subjects in the highest quartile of sodium excretion had mean PRA values 35% lower than those in the lowest quartile [6]. This is why clinicians sometimes ask patients to maintain a liberal sodium intake (greater than 5 g NaCl daily) for several days before testing, to standardize the stimulus.

Age also matters. PRA declines with age. Patients over 65 tend to have lower baseline PRA, partly because of declining nephron mass and partly because of increased arterial stiffness that alters baroreceptor signaling [7]. Interpreting a PRA of 0.5 ng/mL/hr in a 70-year-old requires different context than the same value in a 30-year-old.

What a High PRA Means

Elevated PRA indicates that renin secretion is above the expected set point. The clinical interpretation depends entirely on whether aldosterone is co-elevated or suppressed.

High PRA with high aldosterone points toward secondary hyperaldosteronism. The renin-angiotensin-aldosterone system (RAAS) is firing appropriately in response to a perceived drop in effective arterial blood volume. Common causes include renal artery stenosis, heart failure, cirrhosis, and nephrotic syndrome [1]. Renovascular hypertension from atherosclerotic renal artery stenosis accounts for 1% to 5% of all hypertension cases, and a PRA above 5.0 ng/mL/hr in a patient with resistant hypertension and an abdominal bruit should prompt renal duplex ultrasonography [8].

High PRA with low or normal aldosterone suggests a renin-secreting tumor (reninoma) or, more commonly, medication effect. ACE inhibitors and ARBs block downstream conversion of angiotensin I, causing a compensatory rise in renin without a corresponding aldosterone increase [2]. Diuretics stimulate renin release through volume depletion.

The RAAS Interpretation Framework published by the American Association of Clinical Endocrinologists (AACE) in its 2020 adrenal incidentaloma guidance stratifies results into four quadrants: high renin/high aldosterone (secondary hyperaldosteronism), low renin/high aldosterone (primary aldosteronism), high renin/low aldosterone (adrenal insufficiency or medication effect), and low renin/low aldosterone (hyporeninemic hypoaldosteronism, common in diabetic nephropathy) [9].

A 2008 study in the Journal of Hypertension followed 609 patients with resistant hypertension and found that those with PRA above the 75th percentile had a 2.4-fold higher risk of cardiovascular events over 4.3 years compared to those in the lowest quartile (HR 2.41; 95% CI 1.22 to 4.78) [10].

What a Low PRA Means

Suppressed PRA (below 0.25 ng/mL/hr upright, or below the assay's lower detection limit) is the hallmark of primary aldosteronism. Autonomous aldosterone production expands plasma volume, which suppresses renin through negative feedback at the juxtaglomerular apparatus [2].

Primary aldosteronism is not rare. The PAPY (Primary Aldosteronism Prevalence in Italy) study screened 1,125 newly diagnosed hypertensive patients and found primary aldosteronism in 11.2% of them [11]. A separate analysis of 5,100 hypertensive patients in the German Conn Registry found a prevalence of 5.9% among those referred for specialist evaluation [12]. The Endocrine Society guideline states: "Primary aldosteronism is the most common cause of secondary hypertension and should be considered in all patients with resistant hypertension, hypokalemia, or adrenal incidentaloma" [2].

The screening test is the aldosterone-to-renin ratio (ARR). An ARR of 30 ng/dL per ng/mL/hr or greater, with a concurrent aldosterone above 15 ng/dL, is considered a positive screen [2]. A positive screen requires confirmatory testing, typically an oral sodium loading test or a saline infusion test, before imaging with adrenal CT.

Low PRA also occurs in about 25% to 30% of patients with essential hypertension, a phenotype called low-renin hypertension [13]. These patients tend to be older, Black, and salt-sensitive. They often respond better to calcium channel blockers and thiazide diuretics than to ACE inhibitors or ARBs, because their suppressed RAAS means there is less angiotensin II to block.

Dr. John Funder, who chaired the 2016 Endocrine Society guideline committee, noted in a Lancet Diabetes & Endocrinology commentary: "The tragedy of primary aldosteronism is not its rarity but its routine under-diagnosis. Most patients with an ARR above 30 are never tested" [14].

Medications That Alter PRA Results

Nearly every antihypertensive drug class affects PRA. Testing ideally occurs after a medication washout, but this is not always safe or practical.

ACE inhibitors and ARBs raise PRA by blocking angiotensin II's negative feedback on renin secretion [2]. Beta-blockers suppress PRA by inhibiting sympathetic-mediated renin release from juxtaglomerular cells [1]. Thiazide and loop diuretics raise PRA through volume depletion and reduced sodium delivery to the macula densa [2]. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) raise both PRA and aldosterone, making ARR interpretation unreliable [2].

The Endocrine Society guideline recommends that spironolactone and eplerenone be stopped at least four weeks before ARR testing, and that ACE inhibitors, ARBs, beta-blockers, and central alpha-agonists be stopped at least two weeks before if clinically safe [2]. During the washout, blood pressure can be managed with verapamil (slow-release) and/or hydralazine, neither of which significantly alters PRA.

The 2020 AACE/ACE consensus statement on adrenal and paraganglionic disorders echoes this recommendation, adding that drospirenone-containing oral contraceptives should also be discontinued because drospirenone has antimineralocorticoid activity [9].

A practical point: if a patient's ARR is above 30 while they are taking an ACE inhibitor or ARB (both of which raise renin and should lower the ratio), the screening test is even more convincing, because the medication bias works against a positive result [2].

How Clinicians Use PRA to Guide Treatment

PRA-guided antihypertensive therapy is an approach studied in several randomized trials. The principle is straightforward. Patients with high PRA (indicating RAAS activation) should respond best to drugs that block the RAAS: ACE inhibitors, ARBs, or direct renin inhibitors. Patients with low PRA should respond best to volume-reducing agents: thiazide diuretics or calcium channel blockers.

The PATHWAY-2 trial (N=335) tested spironolactone as add-on therapy for resistant hypertension and found that patients with the lowest baseline renin levels had the greatest systolic blood pressure reduction with spironolactone, averaging 8.7 mmHg greater reduction compared to those with the highest renin levels [15]. Dr. Bryan Williams, the trial's principal investigator, stated in The Lancet: "Plasma renin measurement helps predict who will benefit most from mineralocorticoid receptor antagonism in resistant hypertension" [15].

The Veterans Affairs Cooperative Study on Single-Drug Therapy of Hypertension compared six drug classes in 1,292 men. Response rates to hydrochlorothiazide were highest in men with low baseline PRA (72%), while response rates to captopril were highest in men with high baseline PRA (68%) [16].

Despite this evidence, routine PRA-guided therapy has not been adopted into major guidelines. The 2017 ACC/AHA hypertension guideline does not recommend PRA for routine initial drug selection [17]. The test remains most useful in its established role: screening for primary aldosteronism, evaluating secondary hypertension, and differentiating causes of hypo- or hyperkalemia.

How to Lower Elevated Plasma Renin Activity

Since high PRA typically reflects either volume depletion, RAAS-stimulating medications, or genuine renovascular disease, lowering PRA means treating the underlying cause.

Dietary sodium increase suppresses renin. Increasing NaCl intake from 2 g to 6 g per day reduces PRA by approximately 40% to 60% in sodium-sensitive individuals, as demonstrated in the DASH-Sodium trial sub-analysis [18]. This is a physiologic maneuver, not a treatment recommendation for hypertension (where sodium restriction is standard advice).

Beta-blockers suppress PRA directly. Propranolol 80 mg twice daily reduces PRA by approximately 60% to 75% in most patients [1]. This suppression underlies part of the antihypertensive effect of beta-blockers in high-renin hypertension.

Direct renin inhibitors (aliskiren) bind the catalytic site of renin and reduce PRA by more than 80% at the 300 mg dose [3]. The ALTITUDE trial (N=8,561), however, showed that adding aliskiren to an ACE inhibitor or ARB in diabetic patients increased adverse events (hyperkalemia, hypotension, renal impairment) without cardiovascular benefit, leading the FDA to contraindicate the combination [19].

For renovascular hypertension, renal artery revascularization (angioplasty with stenting) can normalize PRA. The CORAL trial (N=947), though, showed no significant benefit of stenting over medical therapy alone for atherosclerotic renal artery stenosis, with a primary endpoint event rate of 35.1% vs. 35.8% (HR 0.94; 95% CI 0.76 to 1.17) [20]. Stenting is now generally reserved for patients with recurrent flash pulmonary edema or declining renal function refractory to medical management.

How to Raise Suppressed Plasma Renin Activity

Low PRA is most often a finding to diagnose, not a target to treat. In primary aldosteronism, PRA rises naturally after successful adrenalectomy or after starting a mineralocorticoid receptor antagonist like spironolactone [2].

Sodium restriction stimulates PRA. Reducing dietary sodium to below 2 g per day activates the RAAS within 3 to 5 days [18]. This principle is used in confirmatory testing for primary aldosteronism, where failure of PRA to rise despite sodium restriction supports the diagnosis.

Upright posture stimulates renin. Postural stimulation testing (measuring PRA after 4 hours of ambulation compared to a supine baseline) was historically used to differentiate aldosterone-producing adenomas from bilateral adrenal hyperplasia [1]. An aldosterone-producing adenoma typically shows suppressed PRA that fails to rise with posture, while bilateral hyperplasia may show a partial PRA increase.

Diuretic administration raises PRA. A single 40 mg dose of furosemide followed by 2 hours of upright posture can increase PRA by 2- to 5-fold and is sometimes used as a stimulation test in the workup of suspected Bartter syndrome or Gitelman syndrome [1].

In hyporeninemic hypoaldosteronism (type IV renal tubular acidosis), common in patients with diabetic nephropathy, fludrocortisone 0.1 mg daily replaces the missing aldosterone effect but does not raise PRA itself [7]. Treatment focuses on correcting the hyperkalemia and metabolic acidosis rather than normalizing renin.

PRA vs. Direct Renin Concentration: Which Test to Order

Two renin assays exist. PRA (the functional assay) measures enzymatic activity. Direct renin concentration (DRC, also called active renin mass) measures renin protein via immunoassay. Both are valid for ARR screening, but they are not interchangeable.

The 2016 Endocrine Society guideline accepts either assay but specifies different ARR cutoffs: 30 ng/dL per ng/mL/hr for PRA-based ARR, and 3.7 ng/dL per mIU/L for DRC-based ARR [2]. A 2014 meta-analysis in the Journal of the Renin-Angiotensin-Aldosterone System covering 4,904 patients found that DRC-based ARR had a pooled sensitivity of 89% and specificity of 96% for primary aldosteronism, compared to 84% sensitivity and 75% specificity for PRA-based ARR [21].

DRC has better analytical precision at the low end of the range because it avoids the incubation step that introduces variability into PRA measurements [4]. Many reference labs are transitioning from PRA to DRC for this reason. The LC-MS/MS-based DRC assay also has a faster turnaround and is less affected by sample handling errors.

If your lab reports DRC in mIU/L or pg/mL rather than PRA in ng/mL/hr, confirm which ARR formula your endocrinologist uses. Mixing assay types with the wrong cutoff is a common source of false-positive and false-negative screens.